Loading
A phase 1/2 trial of Lurbinectedin in ewing sarcoma, run by Jazz Pharmaceuticals, now recruiting.
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma is a phase 1/2 interventional study registered as NCT05734066 by Jazz Pharmaceuticals, with 60 participants planned, started 2023-05-23 and due to reach its primary completion in 2028-01-28. Interventions recorded: Lurbinectedin. Conditions listed: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lurbinectedin, Jazz Pharmaceuticals, Cytotoxic chemotherapy.
Shares Lurbinectedin, Jazz Pharmaceuticals, Cytotoxic chemotherapy.
Shares Lurbinectedin, Cytotoxic chemotherapy.
Shares Lurbinectedin, Cytotoxic chemotherapy.
Shares Ewing sarcoma, Cytotoxic chemotherapy.
Shares Lurbinectedin, Cytotoxic chemotherapy.
Shares Lurbinectedin, Ewing sarcoma.
Shares Ewing sarcoma, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/